News Center

Discover all of the trending news of the Ipsen Group


150 results

Neuroscience

Ipsen supports awareness of Neuroendocrine Tumors (NET) and ...

NET Cancer Day, a global initiative of the International Neuroendocrine Cancer Alliance (INCA) and…

Rare diseases

Ipsen launches acromunity.com a website designed with patien...

Acromunity.com is intended for patients who have just been diagnosed or patients…

People

Dr Sotirios Stergiopoulos appointed as the new President of ...

Dr Sotirios Stergiopoulos, Senior Vice-President & Head of Global Medical Affairs at Ipsen Bioscience, has…

Event

Ipsen at ESMO 2017

Want to know more about the activities Ipsen is organising and data we are sharing…

Financial information

Ipsen’s First Half 2017 Financial Results

Financial Community: audio broadcast will start at 04:00 CEST Click here to access audio webcast…

Event

Ipsen’s Investor Day

On May 11, 2017, Ipsen hosted an Investor Day during which David Meek (CEO) and…

Group

Discover Ipsen new clinical trials section

Visit the new clinical trials section

Financial information

Ipsen’s 2016 Full Year Results

David Meek, CEO Aymeric Le Chatelier, Executive Vice President, Finance have been presenting Ipsen's 2016…

Neuroscience

Ipsen launches LivingWithNETs.com a new dedicated website fo...

An uncommon and relatively unknown disease Neuroendocrine tumors (NETs) are most commonly found in the…

Oncology

Latest news on the cabozantinib program

During this conference, Exelixis and Ipsen management and invited guest speakers have reviewed…

Neuroscience

FDA Approval of Dysport® for injection for the tr...

A condition in which there is an abnormal increase in muscle tone or stiffness Spasticity…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022